Rocket Pharmaceuticals, Inc.
DE ˙ DB ˙ US77313F1066
2,44 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:9IP1 / Rocket Pharmaceuticals, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership5,930,178 shares
Ownership 6.60%
BlackRock, Inc. ownership in 9IP1 / Rocket Pharmaceuticals, Inc.

2024-01-29 - BlackRock, Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 5,930,178 shares of Rocket Pharmaceuticals, Inc. (DE:9IP1). This represents 6.6 percent ownership of the company. In their previous filing dated 2023-01-31 , BlackRock, Inc. had reported owning 5,587,535 shares, indicating an increase of 6.13 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-01-29 2024-01-29 13G/A 5,587,535 5,930,178 6.13 6.60 -7.04
2023-01-31 2023-01-31 13G/A 3,339,469 5,587,535 67.32 7.10 36.54
2022-02-04 2022-02-04 13G 1,032,071 3,339,469 223.57 5.20 36.84
2017-02-08 2017-02-08 13G/A 1,521,197 1,032,071 -32.15 3.80 -32.14
2017-01-25 2017-01-25 13G/A 1,714,204 1,521,197 -11.26 5.60 -13.85
2016-01-28 2016-01-28 13G 1,714,204 6.50

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 7,834,795 -71,276 -0.90 28,049 1.07 0.0000
2026-02-12 2025-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 7,906,071 791,700 11.13 27,750 19.65 0.0005
2025-11-12 2025-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 7,114,371 -314,305 -4.23 23,193 27.43 0.0004
2025-08-12 2025-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 7,428,676 154,442 2.12 18,200 -62.49 0.0003
2025-05-02 2025-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 7,274,234 176,947 2.49 48,519 -45.61 0.0010
2025-02-07 2024-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 7,097,287 726,566 11.40 89,213 -24.18 0.0018
2024-11-13 2024-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 6,370,721 178,094 2.88 117,667 -11.75 0.0025
2024-08-13 2024-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 6,192,627 262,717 4.43 133,327 -16.54 0.0030
2024-05-10 2024-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 5,929,910 -268 -0.00 159,752 -10.11 0.0037
2024-02-13 2023-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 5,930,178 816,551 15.97 177,727 69.62 0.0045
2023-11-13 2023-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 5,113,627 -22,180 -0.43 104,778 2.68 0.0030
2023-08-11 2023-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 5,135,807 -331,163 -6.06 102,048 8.97 0.0028
2023-05-12 2023-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 5,466,970 -120,565 -2.16 93,649 -14.36 0.0028
2023-02-13 2022-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 5,587,535 1,093,261 24.33 109,348 52.45 0.0034
2022-11-14 2022-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 4,494,274 488,509 12.20 71,727 30.13 0.0024
2022-08-12 2022-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 4,005,765 674,397 20.24 55,120 4.32 0.0018
2022-05-12 2022-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 3,331,368 -8,101 -0.24 52,835 -27.53 0.0014
2022-02-10 2021-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 3,339,469 120,978 3.76 72,902 -24.22 0.0019
2021-11-09 2021-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 3,218,491 48,359 1.53 96,199 -31.48 0.0027
2021-08-11 2021-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 3,170,132 -87,508 -2.69 140,403 -2.86 0.0039
2021-05-07 2021-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 3,257,640 288,920 9.73 144,541 -11.22 0.0042
2021-02-05 2020-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 2,968,720 93,525 3.25 162,802 147.69 0.0052
2020-11-06 2020-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 2,875,195 -107,701 -3.61 65,728 5.28 0.0024
2020-08-14 2020-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 2,982,896 276,944 10.23 62,432 65.39 0.0025
2020-05-01 2020-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 2,705,952 69,676 2.64 37,748 -37.09 0.0018
2020-02-13 2019-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 2,636,276 18,236 0.70 60,001 96.72 0.0023
2019-11-08 2019-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 2,618,040 54,440 2.12 30,501 -20.68 0.0013
2019-08-22 2019-06-30 13F/A-1 ROCKET PHARMACEUTICALS COM 77313F106 2,563,600 447,257 21.13 38,455 3.59 0.0016
2019-08-13 2019-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 2,563,600 447,257 38,455
2019-05-09 2019-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 2,116,343 177,783 9.17 37,121 29.21 0.0017
2019-02-08 2018-12-31 13F ROCKET PHARMACEUTICALS COM 77313F106 1,938,560 470,451 32.04 28,730 -20.52 0.0015
2018-11-09 2018-09-30 13F ROCKET PHARMACEUTICALS COM 77313F106 1,468,109 162,233 12.42 36,146 41.00 0.0016
2018-08-09 2018-06-30 13F ROCKET PHARMACEUTICALS COM 77313F106 1,305,876 1,222,314 1,462.76 25,635 1,535.93 0.0012
2018-05-09 2018-03-31 13F ROCKET PHARMACEUTICALS COM 77313F106 83,562 -254,203 -75.26 1,567 77.87 0.0001
2018-02-09 2017-12-31 13F INOTEK PHARMACEUTICALS COM 45780V102 337,765 3,320 0.99 881 48.07 0.0000
2017-11-14 2017-09-30 13F INOTEK PHARMACEUTICALS COM 45780V102 334,445 -3,118 -0.92 595 -7.18 0.0000
2017-08-10 2017-06-30 13F INOTEK PHARMACEUTICALS COM 45780V102 337,563 -691,196 -67.19 641 -68.84 0.0000
2017-05-12 2017-03-31 13F INOTEK PHARMACEUTICALS COM 45780V102 1,028,759 984,663 2,233.00 2,057 664.68 0.0001
2017-02-10 2016-12-31 13F INOTEK PHARMACEUTICALS COM 45780V102 44,096 -37,400 -45.89 269 -65.20 0.0004
2016-11-08 2016-09-30 13F INOTEK PHARMACEUTICALS COM 45780V102 81,496 0 0.00 773 27.56 0.0011
2016-08-10 2016-06-30 13F INOTEK PHARMACEUTICALS COM 45780V102 81,496 685 0.85 606 1.34 0.0009
2016-05-10 2016-03-31 13F INOTEK PHARMACEUTICALS COM 45780V102 80,811 0 0.00 598 -34.72 0.0010
2016-02-11 2015-12-31 13F INOTEK PHARMACEUTICALS COM 45780V102 80,811 -13,700 -14.50 916 3.15 0.0013
2015-11-13 2015-09-30 13F INOTEK PHARMACEUTICALS COM 45780V102 94,511 94,511 888 0.0014
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.